24 February - 2 March 2018
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
Oily fish and risk of MS
How much oily fish or fish oil people eat may reduce the risk of getting MS. A study found that the proportion who ate fish once a week or several times a month and daily fish oil supplements was lower among people with MS than in those that didn't have MS. The researchers point out that this association between fish intake and reduced MS risk doesn't demonstrate that fish oil causes this effect. Full data will be presented at the AAN (American Academy of Neurology) meeting in April
MS Trust link: Diet
Deaths associated with neurological conditions
A Public Health England report shows that the number of deaths recorded as being related to neurological conditions has increased between 2001 and 2014. The largest increases are deaths related to Parkinson's and nervous system tumours. Deaths reported as related to MS were up by 6%.
Source: Neurological Alliance
MS Trust link: Life expectancy
MS Trust launches 'Move it For MS' exercise campaign for MS Awareness Week
25 April 2019
This MS Awareness Week, we are calling on people with MS to pop on their pumps and introduce a little activity into their daily routine. Staying active doesn’t need to mean running marathons or going to the gym, it’s about doing it at your own level, at your own pace. Doing it YOUR way.
Don’t judge a book by its cover – Becky’s books help the MS Trust
24 April 2019
Our supporter Becky is raising money for the MS Trust with the sale of her beautiful handmade notebooks.
EMA recommends temporary restriction on use of Lemtrada
12 April 2019
The European Medicines Agency has recommended a temporary restriction on people who should start treatment with Lemtrada while a review of side effects is carried out.